Evidence map›Paper›PMID 30627175›Full record

ReviewStem cells international2018

Biomaterial Engineering for Controlling Pluripotent Stem Cell Fate.

Taylor B Bertucci, Guohao Dai

Abstract readReview
In one paragraph

Review in Stem cells international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Human-Induced Pluripotent Stem Cells in Plastic and Reconstructive Surgery.International journal of molecular sciences · 2024
    Review
  3. [Advances in Molecular Regulatory Mechanisms of Jaw Repair and Reconstruction].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Stem cells and common biomaterials in dentistry: a review study.Journal of materials science. Materials in medicine · 2022
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Engineering Cell Systems.Stem cells international · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Taylor B BertucciDepartment of Bioengineering, Northeastern University, Boston, MA 02115, USA.
Guohao DaiDepartment of Bioengineering, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0001-7346-2685

Funding

Differentiating Embryonic Stem Cells Toward Arterial and Venous Endothelial Cells For Vascular RegenerationR01HL118245 · NHLBI · RENSSELAER POLYTECHNIC INSTITUTE · PI DAI, GUOHAO · 2013 to 2017
$1.9M
Elastic printable biomaterials for 3-D bioprinting of vascular conduitR21HD090680 · NICHD · NORTHEASTERN UNIVERSITY · PI DAI, GUOHAO · 2017 to 2018
$425k
Control Arterial-Venous Differentiation Using 3-Dimensional Cell Printing TechnolR21HL102773 · NHLBI · RENSSELAER POLYTECHNIC INSTITUTE · PI DAI, GUOHAO · 2010 to 2011
$384k
NHLBI NIH HHS R01 HL118245NHLBI NIH HHS R21 HL102773NICHD NIH HHS R21 HD090680
6 · The paper itself

Abstract

Pluripotent stem cells (PSCs) represent an exciting cell source for tissue engineering and regenerative medicine due to their self-renewal and differentiation capacities. The majority of current PSC protocols rely on 2D cultures and soluble factors to guide differentiation; however, many other environmental signals are beginning to be explored using biomaterial platforms. Biomaterials offer new opportunities to engineer the stem cell niches and 3D environments for exploring biophysical and immobilized signaling cues to further our control over stem cell fate. Here, we review the biomaterial platforms that have been engineered to control PSC fate. We explore how altering immobilized biochemical cues and biophysical cues such as dimensionality, stiffness, and topography can enhance our control over stem cell fates. Finally, we highlight biomaterial culture systems that assist in the translation of PSC technologies for clinical applications.

Identifiers

PMID30627175
PMCPMC6304878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.